Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
XBiotech Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
XBIT
Nasdaq
2834
NA02
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for XBiotech Inc
XBiotech Inc.'s (NASDAQ:XBIT) top owners are retail investors with 44% stake, while 44% is held by insiders
- Feb 25th, 2024 12:35 pm
XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus
- Jan 4th, 2024 2:00 pm
Companies Like XBiotech (NASDAQ:XBIT) Are In A Position To Invest In Growth
- Dec 5th, 2023 4:10 pm
Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis
- Nov 14th, 2023 2:00 pm
XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
- Sep 26th, 2023 1:00 pm
Individual investors account for 50% of XBiotech Inc.'s (NASDAQ:XBIT) ownership, while insiders account for 35%
- Sep 16th, 2023 2:30 pm
XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer
- Aug 30th, 2023 1:00 pm
XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial
- Aug 8th, 2023 3:47 pm
The past three years for XBiotech (NASDAQ:XBIT) investors has not been profitable
- Jul 25th, 2023 3:53 pm
Here's Why We're Not Too Worried About XBiotech's (NASDAQ:XBIT) Cash Burn Situation
- Jun 28th, 2023 2:36 pm
FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients
- May 22nd, 2023 1:00 pm
XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares
- May 17th, 2023 1:00 pm
XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
- Apr 17th, 2023 1:00 pm
XBiotech Inc.'s (NASDAQ:XBIT) top owners are individual investors with 51% stake, while 36% is held by insiders
- Apr 9th, 2023 2:08 pm
Scroll